MATARAZA JENNIFER MARIE,VAN ELSAS ANDREA,KORMAN ALAN J,HALK EDWARD L.,THUDIUM KENT B,SELBY MARK,SPROUL MARK,LEBLANC HEIDI
申请号:
CO12031267
公开号:
CO6612216A2
申请日:
2012.02.22
申请国别(地区):
CO
年份:
2013
代理人:
摘要:
The invention refers to anti human BTLA antibody with one or more ideal characteristics, including high affinity, neutralization activity, good pharmacology and low antigenicity in human body. The invention also relates to the problem of using the antibody invented at present to treat diseases. In some achievements, the invention refers to the antigen binding (BTL) of an isolated antibody or a part of it that combines B type and T type human lymphocyte (BTL 1933) attenuatorAccording to its initials,1. Contains one or more selected group attributes, including: (a) does not prevent the combination of BTLA and the herpesvirus (HVEM) input mediator;b) cross-react with macaque BTLA; c) exhibits a KD for binding to human BTLA of at most 2.4 X 10-9, and d) exhibits an EC5O of approximately 1 0-100 nM in an in vitro assay that measures the activation of B or T cells In embodiments In addition, the invention relates to an isolated antibody, or an antigen-binding fragment thereof, that binds to human TALA, comprising one or more properties selected from the group consisting of: a) blocking the binding of BTLA to HVEM , b) cross-react with BTLA of macaque; and c) exhibits a KD for binding to human BTLA of at most about 4.6 X10-9.La presente invención se refiere a anticuerpos BTLA antihumanos que tienen una o más propiedades deseables, que incluyen altas afinidades de unión, actividades neutralizantes, buena farmacocinética y baja antigenicidad en sujetos humanos. La invención además se refiere al uso de los anticuerpos de la presente invención en el tratamiento de enfermedades. En ciertas realizaciones, la invención se refiere a un anticuerpo aislado o un fragmento del mismo de unión a antígeno que se une a atenuante de linfocito B y T humano (BTLÁ, según su sigla en inglés), que comprende una o más propiedades seleccionadas del grupo que consiste en: a) no bloquea la unión de BTLA al mediador de entrada del virus del herpes (HVEM); b) reacciona en forma cruzada con BTLA de ma